Hologic issues strong guidance, shares +3.6% AH

|By:, SA News Editor

Hologic (HOLX) expects FQ2 revenue of $605M-$615M; the $610M midpoint is favorable to a $606.5M consensus. The company is only reaffirming its FY14 (ends Sep. '14) revenue guidance, but has slightly raised its EPS guidance to $1.34-$1.38 from $1.32-$1.38 (consensus is at $1.36).

FQ1 Diagnostics sales -6.6% Y/Y to $285.8M, Breast Health +2.6% to $226.5M, GYN Surgical -2.5% to $78.9M, Skeletal Health -10.1% to $21.3M.

Sales/marketing spend fell 12% Y/Y to $83.3M and R&D spend fell 5% to $48.7M, but G&A spend rose 25% to $67.8M.

CEO Stephen MacMillan says Hologic will be focused on improving its "operating performance and growth profile" in 2014, as well as paying down debt; the company had $4.3B in debt at the end of 2013, and $449M in cash/equivalents.

FQ1 results, PR